Fecal Calprotectin in Cystic Fibrosis

NCT00863694 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 106

Last updated 2013-12-13

No results posted yet for this study

Summary

Elevated fecal calprotectin is a biomarker for intestinal inflammation in cystic fibrosis

Conditions

Sponsors & Collaborators

  • Medical College of Wisconsin

    lead OTHER

Principal Investigators

  • Steven Werlin, MD · Medical College of Wisconsin

Eligibility

Min Age
1 Month
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00863694 on ClinicalTrials.gov